CLINICAL TRIALS PROFILE FOR SAPHRIS
✉ Email this page to a colleague
All Clinical Trials for SAPHRIS
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00281320 ↗ | Study of Asenapine in Elderly Subjects With Psychosis (A7501021)(P05717) | Completed | Merck Sharp & Dohme Corp. | Phase 3 | 2006-02-01 | This study evaluates the safety and tolerability of Asenapine in elderly patients with psychosis. |
| NCT00833976 ↗ | Omega-3 Fatty Acids (Lovaza) for Second Generation Antipsychotic-Associated Hypertriglyceridemia | Completed | GlaxoSmithKline | Phase 4 | 2009-07-01 | This is an open-label pilot study of omega-3 fatty acids (Lovaza) for hypertriglyceridemia in subjects who have been on an atypical (second-generation) antipsychotic medication. The investigators hypotheses are that patients who receive Lovaza will experience a significant decrease in triglycerides from baseline. Secondary hypotheses include: Patients will experience a significant decrease in total cholesterol, and Lovaza will be well tolerated. |
| NCT00833976 ↗ | Omega-3 Fatty Acids (Lovaza) for Second Generation Antipsychotic-Associated Hypertriglyceridemia | Completed | Massachusetts General Hospital | Phase 4 | 2009-07-01 | This is an open-label pilot study of omega-3 fatty acids (Lovaza) for hypertriglyceridemia in subjects who have been on an atypical (second-generation) antipsychotic medication. The investigators hypotheses are that patients who receive Lovaza will experience a significant decrease in triglycerides from baseline. Secondary hypotheses include: Patients will experience a significant decrease in total cholesterol, and Lovaza will be well tolerated. |
| NCT00878462 ↗ | An Acceptability Study of Unflavored Asenapine Versus Raspberry Flavored Asenapine in Stable Patients With a Psychotic Disorder (P07010)(COMPLETED) | Completed | Merck Sharp & Dohme Corp. | Phase 2 | 2005-06-29 | This trial was a randomized trial to determine a patient's acceptability of unflavored antipsychotic medication compared to raspberry flavored antipsychotic medication. Patients received 6 total doses of study drug (2 doses of each asenapine formulation) over 3 consecutive days: 2 different formulations each day, 1 in the morning and 1 in the evening. The formulations were: white unflavored, white raspberry flavored, and red raspberry flavored. Patients were given a questionnaire following each dose of study medication (one questionnaire twice per day for 3 days) to measure how acceptable each formulation was. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for SAPHRIS
Condition Name
Clinical Trial Locations for SAPHRIS
Trials by Country
Clinical Trial Progress for SAPHRIS
Clinical Trial Phase
Clinical Trial Sponsors for SAPHRIS
Sponsor Name
